Promising therapeutic targets for antileishmanial drugs.

  title={Promising therapeutic targets for antileishmanial drugs.},
  author={Karl A. Werbovetz},
  journal={Expert opinion on therapeutic targets},
  volume={6 4},
Current treatments for the parasitic disease leishmaniasis are unsatisfactory due to their route of administration, toxicity and expense. Resistance is also developing to first-line antimonial drugs. Fortunately, a handful of antileishmanial agents, such as the orally available compound miltefosine, are currently in clinical trials. In addition, several promising drug targets and lead molecules are being studied with the goal of developing new antileishmanial agents. Drug candidates have been… CONTINUE READING


Publications citing this paper.

Similar Papers

Loading similar papers…